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Abstract: Venoarterial extracorporeal membrane oxygenation
(VA-ECMO) is an invaluable rescue therapy for patients suf-
fering from cardiopulmonary arrest, but it is not without its
drawbacks. There are cases where patients recover their cardiac
function, yet they fail to wean to mechanical conventional ven-
tilation (MCV). The use of high-frequency percussive ventilation
(HFPV) has been described in patients with acute respiratory
failure (RF) who fail MCV. We describe our experience with ﬁve
patients who underwent VA-ECMO for cardiopulmonary arrest
who were successfully weaned from VA-ECMO with HFPV after
failure to wean with MCV. Weaning trials of HFPV a day before
decannulation or at the time of separation from VA-ECMO were
conducted. Primary endpoint data collected include pre- and post-
HFPV partial pressures of oxygen (PaO2) and PaO2/FIO2 (P/F)
ratios measured at 2 and 24 hours after institution of HFPV.
Additional periprocedural data points were collected including
length of time on ECMO, hospital stay, and survival to discharge.
Four of ﬁve patients were placed on VA-ECMO subsequent to
percutaneous coronary intervention. One patient had cardiac
arrest secondary to RF. Mean PaO2 (44 6 15.9 mmHg vs. 354 6
149 mmHg, p < .01) and mean P/F ratio (446 15.9 vs. 3546 149,
p < .01) increased dramatically at 2 hours after the initiation of
HFPV. The improvement inmean PaO2 andP/F ratio was durable
at 24 hours whether or not the patient was returned to MCV (n5
3) or remained on HFPV (n 5 2) (44 6 15.9 mmHg vs. 131 6
68.7 mmHg, p 5 .036 and 44 6 15.9 vs. 169 6 69.9, p < .01,
respectively). Survival to discharge was 80%. The data presented
suggest that HFPV may be used as a strategy to shorten time on
ECMO, thereby reducing the negative effects of the ECMO
circuit and improving its cost efﬁcacy. Keywords: high frequency
percussive ventilation (HFPV), extra-corporeal membrane oxy-
genation (ECMO), volume diffusive respirator (VDR), mechanical
conventional ventilation (MCV). J Extra Corpor Technol. 2018;50:
53–57
Venoarterial extracorporeal membrane oxygenation
(VA-ECMO) has been invaluable as a rescue therapy for
patients suffering from cardiopulmonary arrest, but it is not
without its drawbacks. Because of its serious hemorrhagic,
thromboembolic, and infectious complications, the dura-
tion of VA-ECMO should be limited in patients as long as
their cardiopulmonary status is stable. At our institution
from December 2011 to December 2016, we weaned ﬁve
patients from VA-ECMO to high-frequency percussive
ventilation (HFPV), thereby reducing the time spent on
VA-ECMO.
HFPV is useful in patients with respiratory failure (RF)
who fail mechanical conventional ventilation (MCV) and are
being considered for ECMO. However, we have also used
HFPV to wean or rescue patients from VA-ECMO, in ad-
dition to obviating the need for it. Historically, patients being
treated for severe acute respiratory distress syndrome
(ARDS) or pulmonary failure with ECMO receive “lung
rest” with MCV. Literature on the preferred mode of ven-
tilation in patients being treated for cardiac failure with VA-
ECMO, however, is limited. Some reports suggestHFPVmay
improve oxygenation and ventilation at lower mean and peak
airway pressures than MCV with minimal effect on hemo-
dynamics and reduced regional overdistension and associated
ventilator-induced lung injury. We report our experience
using HFPV to separate ﬁve patients from VA-ECMO
instituted for cardiopulmonary arrest.
METHODS
This study was approved by our local institutional re-
view board. Informed consent was waived because of
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the observational retrospective design of the study. Our
institution’s electronic medical records were queried us-
ing the term ECMO, from December 2011 to December
2016. Forty-six patients were identiﬁed with 34 of them
being VA-ECMO. Of all VA-ECMO cases, ﬁve patients
were weaned from VA-ECMO to HFPV after they failed
to be weaned to MCV. Based on our institution’s algorithm
for RF treatment, HFPV is used in patients who fail MCV
and are being considered for ECMO (1). This algorithm was
applied to these ﬁve patients who were already on ECMO
to facilitate their weaning from ECMO.
Information collected included demographics, data
pertaining to ECMO (time from ECMO initiation to HFPV,
duration of ECMO), and pre- and post-respiratory param-
eters such as fraction of inspired oxygen (FiO2), peak end-
expiratory pressure (PEEP), peak inspiratory pressure (PIP),
tidal volume, partial pressures of arterial oxygen (PaO2), and
PaO2 to FiO2 (P/F) ratios at 2 and 24 hours after initiation of
HFPV, duration ofHFPV (Tables 1–2). Lung compliance and
Murray scores of each patient before HFPV initiation were
calculated using their PIP and chest radiographs.
Statistical Analysis
Baseline demographic and clinical data are presented as
mean6 SD. Continuous data were analyzed with Student’s
t test. A p-value of <.05 was considered statistically signiﬁ-
cant. Analysis was performed using Stata 14.1 (StataCorp,
College Station, TX).
RESULTS
Five VA-ECMO patients were weaned to HFPV after
they failed weaning to MCV. Mean patient age was 546 23
years. All patients underwent ECMO during cardiopul-
monary arrest. Four of them had cardiac arrest during
percutaneous coronary intervention and one went into
cardiopulmonary arrest after being intubated for RF. Pre-
HFPV and HFPV data at 2 and 24 hours are listed in
Table 2. Mean time on ECMO was 5.86 4.7 days. Arterial
blood gas and ventilatory settings just before the institution
of HFPV demonstrated severe hypoxemia with a mean P/F
ratio of 446 15.9 and amean PEEP of 7.86 1.8 cm of H2O.
The mean Murray score was 2.7 6 .7, consistent with the
presence of severe lung injury. The mean PaO2 increased
signiﬁcantly from 446 15.9 to 3546 149 mmHg (p< .01) 2
hours after the initiation of HFPV with corresponding
increase in mean P/F ratio from 44 6 15.9 mmHg to 354 6
149 mmHg (p < .01). The effect of HFPV on oxygenation
was durable 24 hours after initiation of HFPV with a mean
PaO2 of 131 6 68.7 mmHg (p < .036) and the mean P/F
ratio of 1696 149 (p< .01) (Table 2). Mean time on HFPV
was 2.26 2.2 days andmean time on a ventilator was 18.66
12.4 days. Survival to discharge was 80%, with one patient
succumbing to progressive right heart failure after sepa-
ration from ECMO.
DISCUSSION
In this article, we present our experience with HFPV as
a weaning method for VA-ECMO patients who fail
weaning from ECMO to MCV. It appears that in these
patients, improvement in the respiratory function lags
behind improvement of their cardiac function, and there-
fore, does not allow adequate ventilation and oxygenation
onMCV. ECMOhas become an essential rescue therapy in
the management of our critically ill patients suffering from
respiratory or cardiac failure who fail therapy on maximal
ventilator settings and pharmacologic support. As our in-
stitution has gained considerable experience with the use of
ECMO and its complications, we started looking for ways
to limit the time our patients spend on ECMO to decrease
its associated complications. Some of the more severe
causes of morbidity and mortality seen in patients on
ECMO include bleeding, thromboembolic events, in-
fection, hypoxemia, and central nervous system events.
Bleeding complications, which are very common in patients
on ECMO, may be because of the fact that most ECMO
patients need anticoagulation. However, apart from sys-
temic anticoagulation, bleeding might also be a result of
Table 1. Individual patient data.
Patient Etiology of Cardiac Arrest
Etiology of
Respiratory Failure Procedures
Age,
Years Gender Outcome
1 Cardiac arrest during PCI related aortic
dissection
ARDS CPE PCI, CABG, and
aortic repair
61 Male Died, due to right
heart failure
2 Cardiac arrest secondary to anomalous
coronary artery
CPE PCI 16 Female Survived to discharge
3 Cardiac arrest secondary to hypoxemia
from severe pneumonia
Pneumonia CPE None 75 Male Survived to discharge
4 Cardiac arrest during PCI CPE PCI 52 Female Survived to discharge
5 Cardiac arrest during PCI ARDS CPE PCI 64 Male Survived to discharge
CABG, coronary artery bypass grafting; CPE, cardiogenic pulmonary edema; PCI, percutaneous coronary intervention.
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thrombocytopenia and clotting factor deﬁciencies, which
arise when contact of blood with the foreign surface of the
ECMO circuit leads to activations of platelets, leukocytes,
and the coagulation cascade (2). In addition, in a retro-
spective analysis of infections occurring in ECMO patients,
Sun et al. (3) found that duration of ECMO therapy was an
independent risk factor for developing bloodstream in-
fections. In another study by Hsu et al. (4) the authors
found that more than 10 days of ECMOwas associated with
higher rate of infections, with Gram-negative bacilli ac-
counting from up to 78% of cases. Therefore, strategies to
minimize the duration of ECMO therapy must constantly
be sought after. We believed HFPV should be considered
as a possible means to this goal.
HFPV is a unique form of ventilation delivered only by
specially designed ventilator called the volume diffusive
respirator (VDR-4; Percussionaire Corp, Sandpoint, ID).
HFPV has been used in patients with severe respiratory
compromise refractory to MCV. High-frequency ventila-
tion implies that ventilatory modality is capable of de-
livering 150 cycles per minute or more of sub-physiologic
tidal volumes. There are three types of high frequency
ventilation: jet, oscillatory, and percussive ventilation.
High-frequency oscillatory ventilation (HFOV) oscillates
the lung at a constant mean airway pressure allowing for
maintenance of alveolar recruitment while avoiding low
end-expiratory pressure and high peak pressures (5).
Unlike HFOV, HFPV results in stepwise inﬂation and
deﬂation of the lung based on lung compliance and airway
resistance. HFPV delivers pneumatically powered, time-
cycled, pressure-limited, ﬂow-interrupted breaths at lower
than normal tidal volumes at rates of 300–1,200 per minute
superimposed on a respiratory rate of 10–15 per minute.
Compared with MCV, HFPV can achieve equivalent or
superior levels of oxygenation and ventilation at lower
peak and mean airway pressures, thereby reducing the risk
of ventilator-associated lung injury. MCV produces more
turbulent gas ﬂow in the lungs as it requires a larger volume
of gas being delivered in a shorter duration of time. By
contrast, high frequency percussive bursts of gas produced
by HFPV results in more laminar gas patterns resulting in
more efﬁcient and accelerated oxygen delivery to the
Table 2. ECMO and ventilatory variables.
Subject 1 2 3 4 5 Mean 6 SD
Pre-HFPV ventilatory data
Ventilatory mode PRVC PRVC CMV ASV PRVC
Murray’s score 1.8 3.3 3.3 2.3 2.8 2.7 6 .7
PEEP, cm H2O 8 8 10 5 8 7.8 6 1.8
PIP, cm H2O 14 36 19 18 20 21.4 6 8.5
Respiratory rate/min 22 25 16 24 12 19.8 6 5.6
FiO2, % 100 100 100 100 100 100 6 .0
pH 7.4 7.2 7.7 7.3 7.5 7.40 6 .2
PaO2, mmHg 28 61 61 32 38 44 6 15.9
pCO2, mmHg 36 42 27 38 43 37.2 6 6.4
O2 saturation, % 48 84 96 57 76 72.2 6 .2
P/F ratio 28 61 61 32 38 44 6 15.9
2 hour HFPV ventilatory data
Ventilatory mode HFPV HFPV HFPV HFPV HFPV
FiO2, % 100 100 100 100 100 100 6 .0
pH 7.4 7.4 7.3 7.5 7.6 7.4 6 .1
PaO2, mmHg 158 481 230 436 466 354 6 149
pCO2, mmHg 30 45 60 31 40 41.2 6 12.2
O2 saturation, % 99 100 100 100 100 99.8 6 .0
P/F ratio 158 481 230 436 466 354 6 149
24 hour HFPV ventilatory data
Ventilatory mode HFPV HFPV PRVC CMV PRVC
FiO2, % 100 100 50 90 60 80 6 .2
pH 7.4 7.3 7.5 7.4 7.4 7.4 6 .1
PaO2, mmHg 55 221 108 184 90 131 6 68.7
pCO2, mmHg 66 44 35 39 42 45.2 6 12.1
O2 saturation, % 88 100 99 100 97 96.8 6 .1
P/F ratio 55 221 216 204.4 150 169 6 69.9
Duration of ECMO, days 14 4 4 2 5 6.0 6 5.1
Days on ECMO to HFPV 15 1 4 2 5 5.4 6 5.6
Time on HFPV, days 2 6 1 1 1 2.2 6 2.2
Tracheostomy Yes Yes No No Yes
Time on ventilator, days 15 29 10 5 34 18.6 6 12.4
Length of hospital stay, days 17 44 17 12 40 26.0 6 14.8
Survival to discharge No Yes Yes Yes Yes
FiO2, fraction of inspired oxygen; PaO2, partial pressure of oxygen; pCO2, partial pressure of carbon dioxide; P/F ratio, PaO2/FiO2 ratio.
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alveoli. This laminar gas ﬂow also pushes trapped gas against
the walls and creates a countercurrent backﬂow of carbon
dioxide (CO2). The end result of this efﬁcient form of gas
exchange is enhanced oxygenation, ventilation, alveolar
recruitment, and clearance of pulmonary secretions and
inﬂammatory debris (6,7). HFPV is able to offer all of these
beneﬁts without contributing to ventilator-associated lung
injury, barotrauma, or hemodynamic compromise, and there-
fore, we believe it should be considered when attempting to
wean patients from ECMO.
In addition, although the use of ECMO has increased
over the past decade, there is limited evidence available to
guide MCV management in patients on ECMO. “Lung
rest” is the current recommendation but speciﬁc guidelines
are absent. The Extracorporeal Life Support Organiza-
tion’s (ELSO) current recommendations for ventilator
management of patients on ECMO are “reasonable initial
ventilator settings during (ECMO) could be decelerating
ﬂow (pressure control), a respiratory frequency of 4–5 per
minute, modest PEEP (e.g., 10 cm H20 above PEEP, or
a PIP of 20 cm H20). Once patients stabilize and sedation
can be lightened, spontaneous ventilation with pressure
support ventilation can be considered” (8). Whereas other
cohorts, including the ELSO registry, REVA trial, and
CESAR trial used modes of MCV reﬂecting the theme of
“lung rest,” none of these used HFPV (9–11).
Based on our experience with this cohort of patients, we
suggest that HFPV may not only be used to obviate the
need for ECMO, but may rescue patients who are already
on it. Furthermore, there were three recently published
reports in whichHFPVwas used as either a rescuemodality
or weaning method in patients with ARDS on ECMO.
Boscolo et al. (12) described a 48-year-old woman who was
placed on ECMO for septic shock and hypoxemic RF
developed from pneumonia that was refractory to MCV.
Thick bronchial secretions prohibited adequate oxygena-
tion with MCV while on ECMO for 18 days, prompting
a trial of HFPV. Within 20 minutes of a 4-hour HFPV trial,
there was improvement in P/F ratio and mobilization of
secretions. The patient was separated from ECMO the
following day. Blondonnet et al. (13) described a case of
a 17-year-old male with severe ARDS from aspiration
pneumonia who was placed on ECMO after failure to
improve gas exchange with non-ventilatory strategies in-
cluding paralysis, prone positioning, and recruitment ma-
neuvers. Despite ECMO support, oxygenation did not
improve and he was subsequently placed on HFPV. Arterial
blood gas performed in the ﬁrst 30 minutes of HFPV showed
a 500% increase in PaO2. He was weaned from ECMO the
next day. A protocolized use of HFPV for adults with RF on
ECMO was used by Michaels et al. (14) to facilitate alveolar
recruitment and pulmonary recovery, resulting in reduced
duration on ECMO support. In that study, 39 patients were
supported while on ECMO with HFVP resulting in less time
on ECMO, thus avoiding further complications. By initiating
HFPV in this cohort of patients with acute RF, there was
comparable survival, and the ability to wean from ECMO
was two-thirds of the time in comparison with ELSO,
REVA, and CESAR trial (9–11,14).
Considering these aforementioned reports and our own
institutional experience, we suggest HFPV as a possible
weaning or rescue tool for patients on ECMO for ARDS.
Although the physiologic causes of cardiogenic shock varied
among the ﬁve patients being analyzed in this report, they all
nonetheless responded favorably to initiation of HFPV, with
dramatic improvement in their PaO2 and P/F ratios within
a matter of 2 hours with durable response at 24 hours. These
improvements in respiratory status facilitated weaning and
decannulation from ECMO, and four of ﬁve of our patients
survived to discharge, whereas the ﬁfth died of progressive
right heart failure. Our ﬁndings are promising, given how
quickly pulmonary function improved after initiation ofHFPV.
Given ECMO is such a limited resource with signiﬁcant costs
and risks, any strategy that may allow for a decrease in the
duration of extracorporeal life support should be pursued.
However further studies are certainly necessary; based
on our report, HFPV may be considered as a rescue or
weaning modality in patients on ECMO for cardiopul-
monary arrest who fail MCV.
LIMITATIONS
The small sample size of the study potentially hinders the
generalizability of the results, despite achieving statistical
signiﬁcance. Additional limitations include possible in-
complete or inaccurate data collection inherent to a ret-
rospective analysis using chart review. Last, as clinical
practice naturally varies across medical centers, extrapo-
lation of our methods might be of limited value.
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